Intermediate Results of Prospective Observational Study: The 2-year Experience of Ibrutinib Therapy in Relapsed/Refractory Mantle Cell Lymphoma in Clinical Practice

MLA

NK Khuazheva, et al. “Intermediate Results of Prospective Observational Study: The 2-Year Experience of Ibrutinib Therapy in Relapsed/Refractory Mantle Cell Lymphoma in Clinical Practice.” Kliničeskaâ Onkogematologiâ, vol. 12, no. 2, Mar. 2019, pp. 165–72. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....01f4c6af4fc18cba3a007427b0a708b1&authtype=sso&custid=ns315887.

APA

NK Khuazheva, EI Dubrovin, LA Bychenkova, YuB Kochkareva, LA Mukha, Valentina Ivanova, VI Vorob’ev, VA Zherebtsova, & Vadim V. Ptushkin. (2019). Intermediate Results of Prospective Observational Study: The 2-year Experience of Ibrutinib Therapy in Relapsed/Refractory Mantle Cell Lymphoma in Clinical Practice. Kliničeskaâ Onkogematologiâ, 12(2), 165–172.

Chicago

NK Khuazheva, EI Dubrovin, LA Bychenkova, YuB Kochkareva, LA Mukha, Valentina Ivanova, VI Vorob’ev, VA Zherebtsova, and Vadim V. Ptushkin. 2019. “Intermediate Results of Prospective Observational Study: The 2-Year Experience of Ibrutinib Therapy in Relapsed/Refractory Mantle Cell Lymphoma in Clinical Practice.” Kliničeskaâ Onkogematologiâ 12 (2): 165–72. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....01f4c6af4fc18cba3a007427b0a708b1&authtype=sso&custid=ns315887.